Moreover, it could be shown that gefitinib in NSCLC exerts clinical efficacy in 10% of patients only, and this efficacy was associated with specific activating mutations in the EGFR gene (Lynch et al, 2004). This evidence concerns the gene EGFR and non-small cell lung carcinoma.